奥沙利铂联合阿帕替尼和卡培他滨治疗晚期胃癌的临床研究

Clinical Study of Oxaliplatin Combined with Apatinib and Capecitabine in the Treatment of Advanced Gastric Cancer

目的分析奥沙利铂联合阿帕替尼和卡培他滨治疗晚期胃癌患者的临床效果.方法选取2016年3月—2018年1月该院晚期胃癌患者106例为研究对象,随机分为A组(n=53)和B组(n=53),B组予以奥沙利铂联合卡培他滨治疗,A组在B组基础上加用阿帕替尼治疗.对比两组的疗效、肿瘤标志物、不良反应及预后情况.结果A组的总有效率为94.34%,高于B组的71.70%,差异有统计学意义(P<0.05).治疗前,两组的癌胚抗原(carcinoembryonic antigen,CEA)、糖类抗原242(carbohydrate antigen 242,CA242)、糖类抗原125(carbohydrate antigen 125,CA125)水平对比,组间差异无统计学意义(P>0.05);治疗后,A组的CEA、CA242、CA125水平均较B组低,组间差异有统计学意义(P<0.05).两组不良反应发生率对比,差异无统计学意义(P>0.05).A组的无进展生存时间和总生存时间均较B组长,组间差异有统计学意义(P<0.05).结论奥沙利铂联合阿帕替尼和卡培他滨联合治疗晚期胃癌患者,可提高疗效,降低血清肿瘤因子水平,延长患者生存时间,具有安全性.

Objective To analyze the clinical effect of oxaliplatin,apatinib and capecitabine in the treatment of advanced gastric cancer.Methods From March 2016 to January 2018,106 patients with advanced gastric cancer were selected and randomly divided into group A(n=53)and group B(n=53).Group B was treated with oxaliplatin combined with capecitabine,and group A was treated with apatinib on the basis of group B.Efficacy,tumor markers,adverse reactions and prognosis were compared between the two groups.Results The total effective rate of group A was 94.34%(50/53)higher than that of group B(71.70%(38/53)),and the difference was statistically significant(P<0.05).After treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 242(CA242)and carbohydrate antigen 125(CA125)in group A were lower than those in group B,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The progression-free survival time and overall survival time in group A were longer than those in group B,and the difference was statistically significant(P<0.05).Conclusion The combination of oxaliplatin,apatinib and capecitabine in the treatment of advanced gastric cancer can improve the efficacy,reduce the level of serum tumor factors,prolong the survival time of patients,and is safe.